Interferon-gamma and atherosclerosis: pro- or anti-atherogenic?
about
Interferon-gamma induces major histocompatibility class II transactivator (CIITA), which mediates collagen repression and major histocompatibility class II activation by human aortic smooth muscle cellsAbsence of CD36 protects against atherosclerosis in ApoE knock-out mice with no additional protection provided by absence of scavenger receptor A I/IIThe Roles of CD137 Signaling in AtherosclerosisDecorin mimic regulates platelet-derived growth factor and interferon-γ stimulation of vascular smooth muscle cellsThe interferon-gamma-mediated inhibition of lipoprotein lipase gene transcription in macrophages involves casein kinase 2- and phosphoinositide-3-kinase-mediated regulation of transcription factors Sp1 and Sp3.Pleiotrophin (PTN) is expressed in vascularized human atherosclerotic plaques: IFN-{gamma}/JAK/STAT1 signaling is critical for the expression of PTN in macrophages.Adenosine blocks IFN-gamma-induced phosphorylation of STAT1 on serine 727 to reduce macrophage activation.CD200 positive human mesenchymal stem cells suppress TNF-alpha secretion from CD200 receptor positive macrophage-like cells.Analysis of the interferon gamma (rs2430561, +874T/A) functional gene variant in relation to the presence of cardiovascular events in rheumatoid arthritisRegulation of ADAMTS-1, -4 and -5 expression in human macrophages: differential regulation by key cytokines implicated in atherosclerosis and novel synergism between TL1A and IL-17.Atherosclerotic Plaque Stability Is Affected by the Chemokine CXCL10 in Both Mice and Humans.Linking immunity to atherosclerosis: implications for vascular pharmacology--a tribute to Göran K. Hansson.Variants of the Coagulation and Inflammation Genes Are Replicably Associated with Myocardial Infarction and Epistatically Interact in Russians.A Unique Combination of Nutritionally Active Ingredients Can Prevent Several Key Processes Associated with Atherosclerosis In Vitro.Gene expression of adhesion molecules in endothelial cells from patients with peripheral arterial disease is reduced after surgical revascularization and pharmacological treatment.Cytokines and atherosclerosis: a comprehensive review of studies in miceAn overview of cytokine interactions in atherosclerosis and implications for peripheral arterial disease.RFXB and its splice variant RFXBSV mediate the antagonism between IFNgamma and TGFbeta on COL1A2 transcription in vascular smooth muscle cells.Interferon-gamma induces prolyl hydroxylase (PHD)3 through a STAT1-dependent mechanism in human endothelial cellsOxysterols in heart failure.Inflammation and immune system interactions in atherosclerosis.Regulatory T cells in atherosclerosis: critical immune regulatory function and therapeutic potential.The Role of Cytokines in the Development of Atherosclerosis.Inhibition of B7-1 (CD80) by RhuDex® reduces lipopolysaccharide-mediated inflammation in human atherosclerotic lesions.Distinct Differences on Neointima Formation in Immunodeficient and Humanized Mice after Carotid or Femoral Arterial Injury.Interferon-γ: Promising therapeutic target in atherosclerosis.Activation of indoleamine 2,3-dioxygenase-induced tryptophan degradation in advanced atherosclerotic plaques: Tampere vascular study.Interleukin-12 is associated with arterial stiffness in healthy individuals.Cytochrome b5, not superoxide anion radical, is a major reductant of indoleamine 2,3-dioxygenase in human cells.Greater expression of postprandial inflammatory genes in humans after intervention with saturated when compared to unsaturated fatty acids.The effects of endothelial lipase gene (LIPG) variants on inflammation marker levels and atherosclerosis development.Comparison of potential preventive effects of pomegranate flower, peel and seed oil on insulin resistance and inflammation in high-fat and high-sucrose diet-induced obesity mice model.Indoleamine 2,3-dioxygenase enzyme activity correlates with risk factors for atherosclerosis: the Cardiovascular Risk in Young Finns Study.Interleukin-27 enhances TNF-α-mediated activation of human coronary artery endothelial cells.Oncostatin M-enhanced vascular endothelial growth factor expression in human vascular smooth muscle cells involves PI3K-, p38 MAPK-, Erk1/2- and STAT1/STAT3-dependent pathways and is attenuated by interferon-γImmunological aspects of atherosclerosis
P2860
Q24289002-D04FE95B-51A5-4452-881A-162D475BCA53Q24658096-95664ABC-65DA-4DDE-8ED0-BA178DAD5C27Q28076613-AEA0F15C-0D04-4CE2-954E-51D76C5CAFA1Q28658459-1BB20EEC-2352-424E-8942-29AF4F9A5B23Q33369658-F6B27692-CB3F-4B0C-BC6D-2BEDC52C9A21Q33694574-9D30816E-18F5-4D34-8156-DBA6063522D1Q34043933-C4885507-6C6B-4054-BBF3-D06E82DFBD96Q34171231-BE3EBD90-3442-4A84-B2CA-352134063827Q34450615-B68C326D-146C-4C0A-9072-25EAAD619BFEQ34823855-7A00A173-1F52-4E61-A46D-86DDD401E944Q35582482-F0A9615C-1394-4580-B621-C40A6B125139Q35713532-0BDF1F19-02F0-4A47-A1FB-A1E098FFB064Q35866903-049D635D-4019-4305-86C5-00FE4CD7FE48Q35948024-4E96A30C-BA89-4DE8-8C87-F8301DEB86B7Q36691971-7AEA9BB3-E099-47DA-9722-8D73CBCFA9A5Q36802942-9FDED14A-F671-4584-89EE-E8174E6F1781Q37019592-C43E4EBC-F255-418A-AE68-96B59ED19A78Q37273654-70169055-0F44-4822-B539-6C892C59EE51Q37377055-7F815AA8-9C08-4B22-AB14-088FEFA50052Q37572785-E06E8B16-6C1E-474F-A337-E38EDBD263C8Q38083555-4F5D0972-94C2-46E7-BA0A-B185585379DEQ38620803-CBB71774-2719-415F-8CFE-ABB7877A9DE9Q39028288-CBCBDB52-B59C-44DA-B57E-F0CE699789C1Q39185042-17C8DBFE-0CA3-4AC6-BBCC-7D371781D551Q41497361-687B029B-04E0-433F-877D-8766FB80AA81Q42713922-1E58D66D-1D6C-465C-8B92-C9C532AB9EDBQ43235071-385884F8-99F5-4B25-AD38-26168A11EFEEQ44025923-E412A2C6-5DD5-4B9F-8B5E-D2C6D97F9C68Q46734158-85A3DE70-928E-4533-874E-E33152700E5FQ48371152-AE283502-6F1E-4E33-9479-02DE62041AF0Q50994462-0405CC53-C485-4F07-A587-4688C500B546Q51290051-B358BA36-A6F7-41F6-A509-FB6FD5AF66B6Q51762707-8B80F647-9B82-4CED-8723-8C89F7517855Q53339368-9CB61BBE-C211-4B24-AFCB-0973380F9D4FQ58071166-4D7804BC-F5C7-429F-9455-22FC9D9F8A6EQ58197587-E5B05D62-A8D1-4E51-ABCF-C632581C3781
P2860
Interferon-gamma and atherosclerosis: pro- or anti-atherogenic?
description
2005 nî lūn-bûn
@nan
2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Interferon-gamma and atherosclerosis: pro- or anti-atherogenic?
@ast
Interferon-gamma and atherosclerosis: pro- or anti-atherogenic?
@en
type
label
Interferon-gamma and atherosclerosis: pro- or anti-atherogenic?
@ast
Interferon-gamma and atherosclerosis: pro- or anti-atherogenic?
@en
prefLabel
Interferon-gamma and atherosclerosis: pro- or anti-atherogenic?
@ast
Interferon-gamma and atherosclerosis: pro- or anti-atherogenic?
@en
P1476
Interferon-gamma and atherosclerosis: pro- or anti-atherogenic?
@en
P2093
Dipak P Ramji
Elizabeth J Harvey
P356
10.1016/J.CARDIORES.2005.04.019
P577
2005-07-01T00:00:00Z